CONTEXT: The Kidney Disease Quality of Life (KDQOL™) instrument is widely used to assess care of end-stage renal disease (ESRD) patients. OBJECTIVES: This study aimed to demonstrate the measurement properties of the Chinese (simplified characters) version of the KDQOL-Short Form™ (KDQOL-SF™) in ethnic Chinese ESRD patients in Singapore. METHODS: Seventy-eight new ESRD patients, initially conservatively managed, were interviewed and followed-up; 31 later commenced dialysis. Quality of life (with the KDQOL-SF), Karnofsky Performance Status, and estimated glomerular filtration rate (eGFR) were assessed at 0, 3, 6, 9, 12, 18, and 24 months. Nonparametric statistics were used to assess correlation and changes. RESULTS: The patterns of descriptive summary and floor and ceiling effects were similar to those reported in the original English version. Most of the kidney disease-targeted scales and the generic scales of the KDQOL-SF demonstrated 1) criterion validity in terms of correlation with objectively measured and/or subjectively rated variables, 2) convergent/divergent validity in terms of correlation patterns between kidney disease-targeted and generic scales, and 3) responsiveness to change in terms of difference before and after dialysis, except for Work Status. Internal consistency reliability was satisfactory, but that for the Work Status scale was too low (alpha=0.32) and for two other kidney disease-targeted scales, Sexual Function and Dialysis Staff Encouragement, was too high (1.0). CONCLUSION: Most of the scales in the Chinese version of the KDQOL-SF were valid and achieved internal consistency reliability, except for the Work Status scale. Also, the internal consistency reliability of two disease-targeted scales was too high, suggesting room for reduction of some items to reduce burden on respondents.
CONTEXT: The Kidney Disease Quality of Life (KDQOL™) instrument is widely used to assess care of end-stage renal disease (ESRD) patients. OBJECTIVES: This study aimed to demonstrate the measurement properties of the Chinese (simplified characters) version of the KDQOL-Short Form™ (KDQOL-SF™) in ethnic Chinese ESRDpatients in Singapore. METHODS: Seventy-eight new ESRDpatients, initially conservatively managed, were interviewed and followed-up; 31 later commenced dialysis. Quality of life (with the KDQOL-SF), Karnofsky Performance Status, and estimated glomerular filtration rate (eGFR) were assessed at 0, 3, 6, 9, 12, 18, and 24 months. Nonparametric statistics were used to assess correlation and changes. RESULTS: The patterns of descriptive summary and floor and ceiling effects were similar to those reported in the original English version. Most of the kidney disease-targeted scales and the generic scales of the KDQOL-SF demonstrated 1) criterion validity in terms of correlation with objectively measured and/or subjectively rated variables, 2) convergent/divergent validity in terms of correlation patterns between kidney disease-targeted and generic scales, and 3) responsiveness to change in terms of difference before and after dialysis, except for Work Status. Internal consistency reliability was satisfactory, but that for the Work Status scale was too low (alpha=0.32) and for two other kidney disease-targeted scales, Sexual Function and Dialysis Staff Encouragement, was too high (1.0). CONCLUSION: Most of the scales in the Chinese version of the KDQOL-SF were valid and achieved internal consistency reliability, except for the Work Status scale. Also, the internal consistency reliability of two disease-targeted scales was too high, suggesting room for reduction of some items to reduce burden on respondents.
Authors: F Yang; K Griva; T Lau; A Vathsala; E Lee; H J Ng; N Mooppil; M Foo; S P Newman; K S Chia; N Luo Journal: Qual Life Res Date: 2015-03-24 Impact factor: 4.147
Authors: Samar Abd ElHafeez; Sunny A Sallam; Zahira M Gad; Carmine Zoccali; Claudia Torino; Giovanni Tripepi; Hala S ElWakil; Noha M Awad Journal: BMC Nephrol Date: 2012-12-13 Impact factor: 2.388
Authors: Shaoqing Wang; Zhaohui Chen; Ping Fu; Li Zang; Li Wang; Xi Zhai; Fang Gao; Aijing Huang; Yao Zhang Journal: Evid Based Complement Alternat Med Date: 2014-12-10 Impact factor: 2.629
Authors: Olalekan Lee Aiyegbusi; Derek Kyte; Paul Cockwell; Tom Marshall; Mary Dutton; Anita Slade; Neil Marklew; Gary Price; Rav Verdi; Judi Waters; Keeley Sharpe; Melanie Calvert Journal: BMJ Open Date: 2017-06-30 Impact factor: 2.692
Authors: Olalekan Lee Aiyegbusi; Derek Kyte; Paul Cockwell; Tom Marshall; Adrian Gheorghe; Thomas Keeley; Anita Slade; Melanie Calvert Journal: PLoS One Date: 2017-06-21 Impact factor: 3.240
Authors: Derek Kyte; Nicola Anderson; Ram Auti; Olalekan Lee Aiyegbusi; Jon Bishop; Andrew Bissell; Elizabeth Brettell; Melanie Calvert; Marie Chadburn; Paul Cockwell; Mary Dutton; Helen Eddington; Elliot Forster; Gabby Hadley; Natalie J Ives; Louise Jackson; Sonja O'Brien; Gary Price; Keeley Sharpe; Stephanie Stringer; Gael Stephenson; Rav Verdi; Judi Waters; Adrian Wilcockson; Jim Williams Journal: J Patient Rep Outcomes Date: 2020-07-08
Authors: Hwee-Lin Wee; Benjamin Jun Jie Seng; Jia Jia Lee; Kok Joon Chong; Pallavi Tyagi; Anantharaman Vathsala; Priscilla How Journal: Health Qual Life Outcomes Date: 2016-06-24 Impact factor: 3.186